Market Availability and Pricing
Foundayo will become available through Eli Lilly’s LillyDirect program starting April 6. The lowest dose will be priced at $149 per month for self-pay patients, a cost comparable to Novo Nordisk’s oral product. Access through retail pharmacies and telehealth platforms is expected to follow. Market analysts estimate that oral weight-loss drugs could capture approximately 20% of the total GLP-1 market by 2030, driven by the convenience of a daily pill over injectable formulations.
Seasonal Rise in SARS-CoV-2 Circulation
While the weight-loss market expands, public health authorities are monitoring a predictable seasonal uptick in coronavirus activity. As of mid-September, the Centers for Disease Control and Prevention (CDC) estimates that COVID-19 infections are growing or likely growing in 27 to 35 states, depending on the specific reporting period and data source. Wastewater surveillance indicates that activity levels remain “low” nationally, though rates are increasing in the South and West, with Texas, California, Florida, and Washington reporting the highest levels of viral presence.
Dr. William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center, notes that this pattern aligns with the virus’s established seasonal cycle, which typically features two waves per year: one in late summer and another during winter. The current increase is attributed to a combination of colder weather facilitating indoor transmission and the waning of immunity from previous infections or vaccinations. Despite the rise in circulation, national data shows that the proportion of positive tests was approximately 5.5% in the week ending September 5, a figure notably lower than the nearly 11% recorded at the same time last year.
Variant Monitoring and Severity
The World Health Organization (WHO) and the UK Health Security Agency (UKHSA) are closely tracking specific viral lineages. XFG, sometimes referred to as the “Stratus” variant, remains the most common lineage, accounting for an estimated 22% to 39% of recent U.S. cases. Another variant, BA.3.2, known as “Cicada,” has spread to at least 23 countries and 25 U.S. states, representing roughly 5% to 16% of cases. BA.3.2 is designated as a Variant Under Monitoring by the WHO, which currently assesses the public health risk as low due to a lack of evidence indicating increased severity, hospitalization, or mortality compared to other circulating strains.
Surveillance data from the UK and the U.S. suggests that while hospital admissions have increased by approximately 50% in some regions over the past month, this rise correlates with the overall increase in virus circulation rather than a shift toward more severe disease. Health officials emphasize that vulnerable populations, including the elderly, immunocompromised individuals, and those with chronic conditions, remain at higher risk for serious illness. Updated COVID-19 vaccines for the 2026–2027 season are available and recommended for eligible groups to maintain protection against severe outcomes.
Regulatory and clinical attention continues to focus on both the expansion of metabolic treatments and the management of respiratory viruses. The next significant milestones include the broader retail rollout of Foundayo and the anticipated winter surge in respiratory illnesses, which experts expect will follow the current late-summer wave.
